Abstract: The present invention relates to therapeutic and/or prophylactic agents for ocular inflammatory disease, which comprise an interleukin 6 (IL-6) receptor inhibitor as an active ingredient.

Abstract: The object of the present invention is to provide a charged filter medium having excellent filtration performance and a method of producing the charged filter medium. Though the present invention is a charged filter medium comprising a charged laminate formed by laminating and integrating a fine fiber layer in which a median fiber diameter of constituent fibers is less than 2.5 ?m and a basis weight is less than 13 g/m2; and a support fiber layer, a pressure drop of the charged filter medium at a wind speed of 10 cm/s is 24 Pa or less; and a particle collection efficiency of particles having a particle diameter of 0.3 to 0.5 ?m at a wind speed of 10 cm/s is 76% or more, and thus the pressure drop and the particle collection efficiency are well balanced.

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

Abstract: The present invention relates to therapeutic and/or prophylactic agents for ocular inflammatory disease, which comprise an interleukin 6 (IL-6) receptor inhibitor as an active ingredient.

Abstract: Provided is a novel molecule that inhibits the expression of the periostin gene. Also provided are methods of inhibiting the expression of the periostin gene or treating an eye disease using the same.

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

Abstract: A staining composition for staining an ophthalmic membrane when performing the ophthalmic membrane removal, wherein the staining composition comprises a Brilliant Blue G (BBG) derivative as a primary component.

Abstract: The present invention relates to therapeutic and/or prophylactic agents for ocular inflammatory disease, which comprise an interleukin 6 (IL-6) receptor inhibitor as an active ingredient.

Abstract: Methods and compositions for suppressing angiogenesis or neovascularization, as well as methods and compositions that are useful in treatment of a disease or disorder related to angiogenesis or neovascularization. The compositions of the present invention include an effective amount of an ephrinB2, while the methods of the present invention include a step of administering an effective amount of an ephrinB2. The compositions and methods of the present invention is useful in treatment of a disease or disorder related to angiogenesis or neovascularization. The compositions and methods of the present invention may also suppress neovascularization from a retina.

Abstract: Methods for inhibiting DNA synthesis, MAP kinase activation, and tube formation of endothelial cells are provided. Also provided are methods for inhibiting angiogenesis and neovascularization, as well as compositions useful for the methods described herein.

Abstract: A staining composition for staining an ophthalmic membrane when performing the ophthalmic membrane removal, wherein the staining composition comprises a Brilliant Blue G (BBG) derivative as a primary component.